Last reviewed · How we verify
peritoneal dialysate at 37°C temperature
Peritoneal dialysate at 37°C facilitates the removal of uremic waste products and excess fluid from the blood across the peritoneal membrane during peritoneal dialysis.
Peritoneal dialysate at 37°C facilitates the removal of uremic waste products and excess fluid from the blood across the peritoneal membrane during peritoneal dialysis. Used for End-stage renal disease (ESRD) requiring renal replacement therapy, Acute kidney injury in select patients.
At a glance
| Generic name | peritoneal dialysate at 37°C temperature |
|---|---|
| Sponsor | Azienda Ospedaliero-Universitaria di Modena |
| Drug class | Renal replacement therapy solution |
| Modality | Small molecule |
| Therapeutic area | Nephrology |
| Phase | FDA-approved |
Mechanism of action
Peritoneal dialysate is a sterile solution instilled into the peritoneal cavity that acts as a medium for diffusion and ultrafiltration. Waste products and excess electrolytes diffuse from the blood across the peritoneal membrane into the dialysate, while the osmotic gradient created by glucose (or other osmotic agents) in the solution draws excess fluid from the bloodstream. Maintaining the dialysate at body temperature (37°C) optimizes the efficiency of these transport processes.
Approved indications
- End-stage renal disease (ESRD) requiring renal replacement therapy
- Acute kidney injury in select patients
Common side effects
- Peritonitis
- Exit site infection
- Hyperglycemia
- Hypokalemia
- Abdominal discomfort
Key clinical trials
- Peritoneal Dialysis Fluid Cooling and Cardio-Protective Effects (NA)
- Dialysate Temperature in Peritoneal Dialysis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: